Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Investigational New Drugs|June 7, 2012
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancerJ Rodríguez-Pascual, P Sha, E García-García, et al.
Journal of Pediatric Orthopedics. Part B|May 22, 2001
Subacute osteomyelitis in childrenJ L González-López, F J Soleto-Martín, A Cubillo-Martín, et al.
Cirugia Pediatrica : Organo Oficial De La Sociedad Espanola De Cirugia Pediatrica|November 26, 1999
[Obstetric sciatic paralysis: a 29-year experience in a tertiary hospital]J Soleto Martín, J A Rodríguez Durántez, J L González López, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 studyR Garcia-Carbonero, E Elez, P García-Alfonso, et al.
Clinical Pharmacology and Therapeutics|April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With CancerB S Adiwijaya, J Kim, I Lang, et al.
ESMO Open|September 21, 2021
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I studyR Bordonaro, A Calvo, A Auriemma, et al.
British Journal of Cancer|August 3, 2013
Stromal disrupting effects of nab-paclitaxel in pancreatic cancerR Alvarez, M Musteanu, E Garcia-Garcia, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 25, 2020
A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancerX Chen-Zhao, O Hernando, M López, et al.
ESMO Gastrointestinal Oncology|April 23, 2026
Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancerM Fakih, S Gill, K Sampat, et al.
ESMO Open|February 13, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trialT Macarulla, R Pazo Cid, M S Womack, et al.
Pageof 3